Response to "Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia"
Infect Dis Ther
.
2023 Jan;12(1):301-302.
doi: 10.1007/s40121-022-00727-4.
Epub 2022 Nov 22.
Author
Flavio Mantelli
1
Affiliation
1
Dompé Farmaceutici SpA, Via Santa Lucia 6, 20122, Milan, Italy. flavio.mantelli@dompe.com.
PMID:
36417164
PMCID:
PMC9684829
DOI:
10.1007/s40121-022-00727-4
No abstract available
Publication types
Letter